{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:12:29Z","timestamp":1760055149932,"version":"build-2065373602"},"reference-count":15,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["M\u00e9decine et Maladies Infectieuses"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.medmal.2019.09.010","type":"journal-article","created":{"date-parts":[[2019,10,14]],"date-time":"2019-10-14T08:09:14Z","timestamp":1571040554000},"page":"313-315","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Carbapenems versus beta-lactam\/beta-lactamase inhibitors to treat ESBL-producing Enterobacteriaceae infections"],"prefix":"10.1016","volume":"50","author":[{"given":"J.P.","family":"Bru","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Alfandari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Bleibtreu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Chavanet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Gauzit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"X.","family":"Lescure","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Lesprit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Tattevin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.medmal.2019.09.010_bib0080","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1093\/jac\/dks301","article-title":"Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum \u00df-lactamases: a systematic review and meta-analysis","volume":"67","author":"Vardakas","year":"2012","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"10.1016\/j.medmal.2019.09.010_bib0085","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.ijantimicag.2018.07.021","article-title":"Beta-lactam\/beta-lactamase inhibitors versus carbapenem for bloodstream infections due to extended spectrum beta-lactamase producing Enterobacteriaceae: Systematic review and meta-analysis","volume":"52","author":"Sfeir","year":"2018","journal-title":"Intern J Antimicrob Agents"},{"issue":"10","key":"10.1016\/j.medmal.2019.09.010_bib0090","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1093\/jac\/dky168","article-title":"Clinical effectiveness of carbapenems versus alternative antibiotics for treating ESBL-producing Enterobacteriaceae bacteraemia: a systematic review and meta-analysis","volume":"73","author":"Son","year":"2018","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"10.1016\/j.medmal.2019.09.010_bib0095","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofx099","article-title":"Comparison between Carbapenems and \u03b2-Lactam\/\u03b2- Lactamase inhibitors in the treatment for bloodstream infections caused by extended-spectrum \u03b2-Lactamase- producing Enterobacteriaceae: a systematic review and meta-analysis","volume":"4","author":"Muhammed","year":"2017","journal-title":"Open Forum Infectious Diseases"},{"issue":"7","key":"10.1016\/j.medmal.2019.09.010_bib0100","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00365-16","article-title":"A Multinational Preregistered Cohort Study of -Lactam\/-Lactamase Inhibitor Combinations for Treatment of Bloodstream Infections Due to Extended-Spectrum-\u03b2-Lactamase-Producing Enterobacteriaceae","volume":"60","author":"Guti\u00e9rrez-Guti\u00e9rrez","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1016\/j.medmal.2019.09.010_bib0105","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1093\/cid\/cir790","article-title":"\u03b2-Lactam\/\u03b2-Lactam Inhibitor Combinations for the treatment of bacteremia due to extended-spectrum b-lactamase\u2013Producing Escherichia coli: a post hoc analysis of prospective cohorts","volume":"54","author":"Rodr\u00edguez-Bano","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"9","key":"10.1016\/j.medmal.2019.09.010_bib0110","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1093\/cid\/civ003","article-title":"Carbapenem Therapy Is Associated With Improved Survival Compared With Piperacillin- Tazobactam for Patients With Extended- Spectrum \u03b2-Lactamase Bacteremia","volume":"60","author":"Tamma","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"10","key":"10.1016\/j.medmal.2019.09.010_bib0115","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1001\/jama.2018.12163","article-title":"Effect of Piperacillin-Tazobactam vs. Meropenem on 30-day mortality for patients with E coli or Klebsiella pneumoniae bloodstream infection and ceftriaxone resistance-a randomized clinical trial","volume":"320","author":"Harris","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.medmal.2019.09.010_bib0120","unstructured":"EUCAST 2015 warnings concerning antimicrobial susceptibility testing products or procedures. http:\/\/www.eucast.org\/ast_of_bacteria\/warnings\/"},{"year":"2019","series-title":"Association with 30-day mortality and MIC in patients treated with piperacillin\/tazobactam for Escherichia coli and Klebsiella pneumoniae bloodstream infections that are non-susceptible to ceftriaxone from patients enrolled in the MERINO trial","author":"Henderson","key":"10.1016\/j.medmal.2019.09.010_bib0125"},{"key":"10.1016\/j.medmal.2019.09.010_bib0130","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1093\/jac\/dky453","article-title":"OXA-1 b-lactamase and non-susceptibility to penicillin\/b-lactamase inhibitor combinations among ESBL-producing Escherichia coli","volume":"74","author":"Livermore","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.medmal.2019.09.010_bib0135","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ijantimicag.2016.09.027","article-title":"Piperacillin\/tazobactam as an alternative antibiotic therapy to carbapenems in the treatment of urinary tract infections due to extended-spectrum \u03b2-lactamase-producing Enterobacteriaceae: an in silico pharmacokinetic study","volume":"49","author":"Guet-Revillet","year":"2017","journal-title":"Intern J Antimicrob Agents"},{"issue":"5","key":"10.1016\/j.medmal.2019.09.010_bib0140","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02306-17","article-title":"Population pharmacokinetics of Piperacillin in sepsis patients: should alternative dosing strategies be considered?","volume":"62","author":"Andersen","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.medmal.2019.09.010_bib0145","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/2050-6511-15-21","article-title":"Assessment of pharmacokinetic changes of meropenem during therapy in septic critically ill patients","volume":"15","author":"Goncalves-Pereira","year":"2014","journal-title":"BMC Pharmacol Toxicol"},{"issue":"2","key":"10.1016\/j.medmal.2019.09.010_bib0150","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1097\/CCM.0000000000002836","article-title":"Prolonged infusion Piperacillin-Tazobactam decreases mortality and improves outcomes in severely ill patients: results of a systematic review and meta-analysis","volume":"46","author":"Rhodes","year":"2018","journal-title":"Crit Care Med"}],"container-title":["M\u00e9decine et Maladies Infectieuses"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0399077X19305694?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0399077X19305694?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T01:17:56Z","timestamp":1759972676000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0399077X19305694"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":15,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["S0399077X19305694"],"URL":"https:\/\/doi.org\/10.1016\/j.medmal.2019.09.010","relation":{},"ISSN":["0399-077X"],"issn-type":[{"type":"print","value":"0399-077X"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Carbapenems versus beta-lactam\/beta-lactamase inhibitors to treat ESBL-producing Enterobacteriaceae infections","name":"articletitle","label":"Article Title"},{"value":"M\u00e9decine et Maladies Infectieuses","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medmal.2019.09.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}